Olema Pharmaceuticals (OLMA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.63
- Surprise
- —
- Score today
- 4.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Olema Oncology Reports Third Quarter 2026 Financial and Operating Results — fiscal.ai, 2026-11-10
- Olema Pharmaceuticals Q3 EPS $(0.73) Misses $(0.63) Estimate — benzinga, 2026-11-10
Where TrendMatrix's rating stands now
TrendMatrix currently rates OLMA Sell at 4.7/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Pipeline: palazestrant
- DATA_ISSUE: analyst_target_implausible (raw $36.50 vs price $7.24 — ratio 5.0×). Rejected, falling back to technical TP.
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.24
- Price target
- $7.47
- Stop
- $6.73
- Upside to target
- +3.2%
Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.
OLMA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $644.0M
- P/E (fwd)
- -2.8
- 52-week range
- $6.24–$36.26
- Off 52-week high
- 80.0%
- RSI (14)
- 52
- Volume vs avg
- 0.20×
- Score today
- 4.7/10